BioSpace News Archive

Patients living with AHP suffer from chronic debilitating symptoms such as severe abdominal pain and often seek care from gastroenterologists

The Supreme Cannabis Company, Inc. (“Supreme Cannabis” or the “Company”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced its expected revenue for the fiscal fourth quarter ended June 30, 2019 and provided guidance for fiscal 2020

CRB is excited to announce the promotion of Ben Skowronski to the leader of the Maryland office.

Datavant announced today its selection by the People-Centered Research Foundation (PCRF) to de-identify and link patient data across PCORnet, the National Patient-Centered Clinical Research Network.

New patents further expand the Company’s intellectual property estate for capturing and detecting rare cells of interest, including circulating tumor cells, to aid in the management of patients with cancer

Transaction Creates Expanded Portfolio of Cloud-Based Capabilities to Advance Clinical Development

Target Group Inc. (“Target Group” or the “Company”) (OTCQB: CBDY) is pleased to announce, that effective August 8, 2019, it has entered into an exclusive licensing, manufacturing and distribution agreement with cGreen Inc. for a period of 10 years.

Compulink Healthcare Solutions is excited to announce the acquisition of MyEyeStore, an e-commerce solution in ophthalmic healthcare focusing primarily on contact lens re-ordering with the ability for optometry and ophthalmology practices to also sell other recommended products directly to the patient.

Duchesnay USA, a pharmaceutical company that specializes in women’s health, is pleased to announce the launch of the new Osphena® (ospemifene) website

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, provided an update on the first 20 patients enrolled in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 in combination with radiation therapy in newly-diagnosed, MGMT-unmethylated GBM.